| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.039 | 0.4 |